Aminoglycosides: Difference between revisions
From IDWiki
No edit summary |
No edit summary |
||
| Line 1: | Line 1: | ||
| − | = Dosing = |
+ | == Dosing == |
| − | == Initial == |
+ | === Initial === |
If actual body weight more than 20% higher than ideal body weight, need to calculate adjusted body weight (ABW) |
If actual body weight more than 20% higher than ideal body weight, need to calculate adjusted body weight (ABW) |
||
| Line 7: | Line 7: | ||
$$ABW = IBW + 0.4 \times (actual BW - IBW)$$ |
$$ABW = IBW + 0.4 \times (actual BW - IBW)$$ |
||
| − | == Traditional q8h dosing == |
+ | === Traditional q8h dosing === |
* Used for Enterococcus IE, meningitis, septic shock, ascites, AKI/CKD, prefnancy, surgical prophylaxis, burns, osteomyelitis |
* Used for Enterococcus IE, meningitis, septic shock, ascites, AKI/CKD, prefnancy, surgical prophylaxis, burns, osteomyelitis |
||
* 1.7mg/kg (5-7.5mg/kg amikacin) |
* 1.7mg/kg (5-7.5mg/kg amikacin) |
||
| − | == Extended interval dosing == |
+ | === Extended interval dosing === |
* 7mg/kg (15mg/kg amikacin) |
* 7mg/kg (15mg/kg amikacin) |
||
| Line 21: | Line 21: | ||
* CrCl ≤19 don't use |
* CrCl ≤19 don't use |
||
| − | == Dialysis == |
+ | === Dialysis === |
* Pre-HD levels with post-HD doses, though this may change |
* Pre-HD levels with post-HD doses, though this may change |
||
| − | == Synergy == |
+ | === Synergy === |
* 1mg/kg divided q8-12h, peak target 3-5, trough <2 |
* 1mg/kg divided q8-12h, peak target 3-5, trough <2 |
||
| − | == Monitoring == |
+ | === Monitoring === |
| − | == Peak == |
+ | === Peak === |
* 30min after third? dose |
* 30min after third? dose |
||
| Line 37: | Line 37: | ||
* If below target, increase dose |
* If below target, increase dose |
||
| − | == Trough == |
+ | === Trough === |
* Prior to 4th dose, or a random level at 24-48h in renal failure |
* Prior to 4th dose, or a random level at 24-48h in renal failure |
||
| Line 45: | Line 45: | ||
* If above target, increase interval |
* If above target, increase interval |
||
| − | == Hartford Nomogram == |
+ | === Hartford Nomogram === |
 |
 |
||
| − | = Origin = |
+ | == Origin == |
* Derived from Streptomyces spp (mycins & kacins) or Micromonospora spp (micins) |
* Derived from Streptomyces spp (mycins & kacins) or Micromonospora spp (micins) |
||
| − | = Mechanism = |
+ | == Mechanism == |
* Requires electron transport chain (ETC) to cross over the membrane |
* Requires electron transport chain (ETC) to cross over the membrane |
||
| Line 59: | Line 59: | ||
* Reversibly binds 30S ribosomal subunit, which stops proofreading and causes accumulation of bad proteins |
* Reversibly binds 30S ribosomal subunit, which stops proofreading and causes accumulation of bad proteins |
||
| − | = Spectrum of Activity = |
+ | == Spectrum of Activity == |
* Good coverage of Gram-negative aerobes |
* Good coverage of Gram-negative aerobes |
||
| Line 67: | Line 67: | ||
* Can cover Gram-positives if cell wall is disrupted (e.g. by beta-lactam) |
* Can cover Gram-positives if cell wall is disrupted (e.g. by beta-lactam) |
||
| − | = Resistance = |
+ | == Resistance == |
* Altered 50S ribosomal subunit |
* Altered 50S ribosomal subunit |
||
| Line 75: | Line 75: | ||
* Aminoglycoside-modifying enzymes (Enterococcus) |
* Aminoglycoside-modifying enzymes (Enterococcus) |
||
| − | = PK/PD = |
+ | == PK/PD == |
* Poor membrane penetration, therefore doesn't cross over into lungs and CSF |
* Poor membrane penetration, therefore doesn't cross over into lungs and CSF |
||
| Line 82: | Line 82: | ||
* Displays concentration-depedent killing with a prolonged post-antibiotic effect (2-13 hours) |
* Displays concentration-depedent killing with a prolonged post-antibiotic effect (2-13 hours) |
||
| − | = Side Effects = |
+ | == Side Effects == |
* Nephrotoxicity (0-50%), usually non-oliguric AKI with decreased Ca/Mg resorption, often reversible |
* Nephrotoxicity (0-50%), usually non-oliguric AKI with decreased Ca/Mg resorption, often reversible |
||
| Line 97: | Line 97: | ||
* Rarely, neuromuscular blockade |
* Rarely, neuromuscular blockade |
||
| − | = Monitoring = |
+ | == Monitoring == |
* Trough levels |
* Trough levels |
||
Revision as of 05:50, 16 August 2019
Dosing
Initial
If actual body weight more than 20% higher than ideal body weight, need to calculate adjusted body weight (ABW)
$$ABW = IBW + 0.4 \times (actual BW - IBW)$$
Traditional q8h dosing
- Used for Enterococcus IE, meningitis, septic shock, ascites, AKI/CKD, prefnancy, surgical prophylaxis, burns, osteomyelitis
- 1.7mg/kg (5-7.5mg/kg amikacin)
Extended interval dosing
- 7mg/kg (15mg/kg amikacin)
- Use Hartford nomogram with a random level (but remember to halve the amikacin level first)
- CrCl ≥60 q24h
- CrCl 40-59 q36h
- CrCl 20-39 q48h
- CrCl ≤19 don't use
Dialysis
- Pre-HD levels with post-HD doses, though this may change
Synergy
- 1mg/kg divided q8-12h, peak target 3-5, trough <2
Monitoring
Peak
- 30min after third? dose
- Response is based on peak:MIC ratio, target is 8-10 times
- If below target, increase dose
Trough
- Prior to 4th dose, or a random level at 24-48h in renal failure
- Side effects are predicted by trough levels
- Tobra <0.5 (extended) or <2 (traditional)
- Amikacin <1 (extended) or <?? (traditional)
- If above target, increase interval
Hartford Nomogram
Origin
- Derived from Streptomyces spp (mycins & kacins) or Micromonospora spp (micins)
Mechanism
- Requires electron transport chain (ETC) to cross over the membrane
- Anaerobes are therefore inherently resistant
- Reversibly binds 30S ribosomal subunit, which stops proofreading and causes accumulation of bad proteins
Spectrum of Activity
- Good coverage of Gram-negative aerobes
- Except Stenotrophomonas and Burkholderia
- Streptomycin also covers mycobacterium
- Some protozoal coverage
- Can cover Gram-positives if cell wall is disrupted (e.g. by beta-lactam)
Resistance
- Altered 50S ribosomal subunit
- Decreased uptake and accumulation (Pseudomonas)
- Decreased membrane permeability
- Efflux (E. coli)
- Aminoglycoside-modifying enzymes (Enterococcus)
PK/PD
- Poor membrane penetration, therefore doesn't cross over into lungs and CSF
- Half-life 2-3 hours (longer in CKD)
- Excreted 99% unchanged in urine
- Displays concentration-depedent killing with a prolonged post-antibiotic effect (2-13 hours)
Side Effects
- Nephrotoxicity (0-50%), usually non-oliguric AKI with decreased Ca/Mg resorption, often reversible
- Decreased protein synthesis
- Decreased cellular respiration
- Increased apoptosis
- Necrosis in proximal tubules
- Ototoxicity (0-60%), irreversible
- Cumulative effect
- Distribute into the perilymph of the ear, and cause free radical formation causing apoptosis of hair cells
- Needs hearing tests, because it can be subclinical
- Monitor audiometry weekly
- Vestibulotoxicity (0-20%), irreversible
- Rarely, neuromuscular blockade
Monitoring
- Trough levels
- Creatinine
- Weekly audiometry
